• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chemotherapy: International Journal of Experimental and Clinical Chemotherapy >Comparative activity of cefditoren and other oral beta-lactams against nonpneumococcal streptococci.
【24h】

Comparative activity of cefditoren and other oral beta-lactams against nonpneumococcal streptococci.

机译：头孢托仑和其他口服β-内酰胺类药物对非肺炎球菌链球菌的比较活性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: In vitro studies of cefditoren activity have focused primarily on Streptococcus pneumoniae and other bacterial species isolated from patients with respiratory infections, but relatively few reports have been published describing the activity of cefditoren against clinical isolates of nonpneumococcal streptococci. METHODS: Cefditoren activity was determined by broth microdilution (M7-A5, NCCLS, 2000) for 450 viridans group streptococci, 917 Streptococcus pyogenes and 800 other beta-hemolytic streptococci collected throughout the US during 1999-2000. RESULTS: Against viridans group streptococci, cefditoren (MIC(90), 0.5 microg/ml) was 4- to 32-fold more active than the other beta-lactams tested (penicillin ampicillin, amoxicillin-clavulanate, cefprozil and cefuroxime). The difference in activity between cefditoren and the other beta-lactams was greater for penicillin-nonsusceptible isolates (MIC(90s), 1 microg/ml versus 8-32 microg/ml) than among penicillin-susceptible isolates (MIC(90s), 0.12 versus 0.25- 1 microg/ml). Cefditoren also demonstrated potent activity against S. pyogenes (MIC(90), 0.015 microg/ml) and other beta-hemolytic streptococci (MIC(90), 0.06 microg/ml), comparable to that of the other beta-lactams. CONCLUSIONS: The activity demonstrated by cefditoren against nonpneumococcal streptococci, including beta-lactam- and macrolide-resistant isolates, suggests that this agent holds promise as therapy for infections caused by all clinically significant species of streptococci. Copyright 2001 S. Karger AG, Basel
机译：背景：头孢托仑活性的体外研究主要集中于肺炎链球菌和其他从呼吸道感染患者中分离出的细菌，但很少有报道报道头孢托仑对非肺炎球菌链球菌临床分离株的活性。方法：通过肉汤微稀释法（M7-A5，NCCLS，2000）测定头孢托仑的活性，该蛋白在1999-2000年期间在美国范围内收集了450个vi虫类链球菌，917个化脓性链球菌和800个其他β-溶血性链球菌。结果：针对viridis组的链球菌，头孢托仑（MIC（90），0.5微克/毫升）的活性比其他测试的β-内酰胺（青霉素氨苄青霉素，阿莫西林-克拉维酸盐，头孢普罗尔和头孢呋辛）高4至32倍。对青霉素不敏感的菌株（MIC（90s），1 microg / ml对8-32 microg / ml），头孢托仑和其他β-内酰胺的活性差异大于对青霉素敏感的菌株（MIC（90s），0.12相对于0.25-1微克/毫升）。头孢托仑还显示出对化脓性链球菌（MIC（90），0.015 microg / ml）和其他β-溶血性链球菌（MIC（90），0.06 microg / ml）的有效活性，与其他β-内酰胺类药物相当。结论：头孢托仑对非肺炎球菌链球菌（包括对β-内酰胺和大环内酯类耐药的分离株）表现出的活性表明，该药有望用于治疗由临床上所有重要链球菌引起的感染。版权所有2001 S. Karger AG，巴塞尔

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号